



16014830

UNITED STATES OF AMERICA  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0123
Expires:	March 31, 2016
Estimated average burden hours per response.....	12.00

AKB

**ANNUAL AUDITED REPORT**  
**FORM X-17A-5**  
**PART III**

SEC  
Mail Processing  
Section  
MAR 17 2016  
Washington DC

SEC FILE NUMBER
8-68384

FACING PAGE  
**Information Required of Brokers and Dealers Pursuant to Section 17 of the  
Securities Exchange Act of 1934 and Rule 17a-5 Thereunder**

REPORT FOR THE PERIOD BEGINNING 01/01/15 AND ENDING 12/31/15  
MM/DD/YY MM/DD/YY

**A. REGISTRANT IDENTIFICATION**

NAME OF BROKER-DEALER: American Medtech Equity Advisors, LLC

OFFICIAL USE ONLY
FIRM I.D. NO.

ADDRESS OF PRINCIPAL PLACE OF BUSINESS: (Do not use P.O. Box No.)

708 Third Avenue, 5th fl.

(No. and Street)

New York

NY

10017

(City)

(State)

(Zip Code)

NAME AND TELEPHONE NUMBER OF PERSON TO CONTACT IN REGARD TO THIS REPORT

(Area Code - Telephone Number)

**B. ACCOUNTANT IDENTIFICATION**

INDEPENDENT PUBLIC ACCOUNTANT whose opinion is contained in this Report\*

Breard & Associates, Inc.

(Name - if individual, state last, first, middle name)

9221 Corbin Avenue, suite 170

Northbridge

CA

91324

(Address)

(City)

(State)

(Zip Code)

**CHECK ONE:**

- Certified Public Accountant
- Public Accountant
- Accountant not resident in United States or any of its possessions.

FOR OFFICIAL USE ONLY

\*Claims for exemption from the requirement that the annual report be covered by the opinion of an independent public accountant must be supported by a statement of facts and circumstances relied on as the basis for the exemption. See Section 240.17a-5(e)(2)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.


AKB

57


OATH OR AFFIRMATION

I, Daniel S. D'Agostino, Jr., swear (or affirm) that, to the best of my knowledge and belief the accompanying financial statement and supporting schedules pertaining to the firm of American Medtech Equity Advisors, LLC, as of December 31, 2015, are true and correct. I further swear (or affirm) that neither the company nor any partner, proprietor, principal officer or director has any proprietary interest in any account classified solely as that of a customer, except as follows:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

  
Signature

Managing Member  
Title



Notary Public

NEAL HABER  
Notary Public, State of New York  
No. 43212  
Qualified in Westchester County  
Commission Expires June 30, 2019

This report \*\* contains (check all applicable boxes):

- (a) Facing Page.
- (b) Statement of Financial Condition.
- (c) Statement of Income (Loss).
- (d) Statement of Changes in Financial Condition.
- (e) Statement of Changes in Stockholders' Equity or Partners' or Sole Proprietors' Capital.
- (f) Statement of Changes in Liabilities Subordinated to Claims of Creditors.
- (g) Computation of Net Capital.
- (h) Computation for Determination of Reserve Requirements Pursuant to Rule 15c3-3.
- (i) Information Relating to the Possession or Control Requirements Under Rule 15c3-3.
- (j) A Reconciliation, including appropriate explanation of the Computation of Net Capital Under Rule 15c3-1 and the Computation for Determination of the Reserve Requirements Under Exhibit A of Rule 15c3-3.
- (k) A Reconciliation between the audited and unaudited Statements of Financial Condition with respect to methods of consolidation.
- (l) An Oath or Affirmation.
- (m) A copy of the SIPC Supplemental Report.
- (n) A report describing any material inadequacies found to exist or found to have existed since the date of the previous audit.

\*\*For conditions of confidential treatment of certain portions of this filing, see section 240.17a-5(e)(3).

Report of Independent Registered Public Accounting Firm

To the Member of  
American Medtech Equity Advisors, LLC:

We have audited the accompanying statement of financial condition of American Medtech Equity Advisors, LLC ("the Company") as of December 31, 2015, and the related notes (the "financial statements"). These financial statements are the responsibility of American Medtech Equity Advisors, LLC's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of American Medtech Equity Advisors, LLC as of December 31, 2015, in conformity with accounting principles generally accepted in the United States.



Breard & Associates, Inc.  
Certified Public Accountants

New York, New York  
February 24, 2016

**American Medtech Equity Advisors, LLC**  
**Notes to Financial Statements**  
**December 31, 2015**

**Note 1: GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*General*

American Medtech Equity Advisors, LLC (dba AmeriTech Advisors) (the "Company") was organized in the State of Delaware on March 25, 2009. The Company is registered with the Securities and Exchange Commission ("SEC"), a member of the Financial Industry Regulatory Authority ("FINRA"), and the Securities Investor Protection Corporation ("SIPC").

The Company provides merger and acquisition advisory and relating consulting services.

Under its membership agreement with FINRA and pursuant to Rule 15c3-1(k)(2)(i), the Company does not execute or clear securities transactions for customers. Accordingly, the Company is exempt from the requirement of Rule 15c3-3 under the Securities Exchange Act of 1934 pertaining to the possession or control of customer assets and reserve requirements.

*Summary of Significant Accounting Policies*

The Company's financial statements are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America, whereby revenues, if any, from advisory and consulting fees are recognized when earned and expenses are recognized when incurred.

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Accounts receivable are stated at face amount with no allowance for doubtful accounts. An allowance for doubtful accounts is not considered necessary because probable uncollectible accounts are immaterial.

Equipment and software are stated at cost. Depreciation is provided for by the straight-line method for financial statement purposes based upon the estimated useful lives of the assets. Asset lives for Equipment and Software range from 3 to 5 years for financial statement purposes. Repairs and maintenance to these assets are charged to expense as incurred; major improvements enhancing the function and/or useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized.

**American Medtech Equity Advisors, LLC**  
**Notes to Financial Statements**  
**December 31, 2015**

**Note 1: GENERAL AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
(CONTINUED)**

The Company is treated as a disregarded entity for federal income tax purposes, in accordance with single member limited liability company rules. All tax effects of the Company's income or loss are passed through to the member. Therefore, no provision or liability for Federal Income Taxes is included in these financial statements.

**Note 2: EQUIPMENT AND SOFTWARE (NET)**

Equipment and software are recorded net of accumulated depreciation and summarized by major classification as follows:

		<u>Useful Life</u>
Computer and equipment	\$ 2,363	3-5
Software	<u>423</u>	3-5
Total cost of property and equipment	2,786	
Less: accumulated depreciation	<u>(2,526)</u>	
Equipment and software, net	<u>\$ 260</u>	

Depreciation expense for the year ended December 31, 2015 was \$383.

**Note 3: INCOME TAXES**

As discussed in the Summary of Significant Accounting Policies (Note 1), the Company operates as a limited liability company treated as a disregarded entity for federal tax purposes. Accordingly, all tax effects of the Company's income or loss are passed through to the member and no provision or liability for Federal Income Taxes is included in these financial statements.

The Company is required to file income tax returns in state and local tax jurisdictions. The Company's tax returns are subject to examination by taxing authorities in the jurisdictions in which it operates in accordance with the normal statutes of limitations in the applicable jurisdiction. The statute of limitations for state purposes is generally three years, but may exceed this limitation depending upon the jurisdiction involved. Returns that were filed within the applicable statute remain subject to examination. As of December 31, 2015, the taxing authorities have not proposed any adjustment to the Company's tax position.

**American Medtech Equity Advisors, LLC**  
**Notes to Financial Statements**  
**December 31, 2015**

**Note 4: RELATED PARTY TRANSACTIONS**

As of December 31, 2015, there were no related party transactions

**Note 5: CONCENTRATIONS OF CREDIT RISK**

The Company is engaged in various trading and brokerage activities in which counter-parties primarily include broker-dealers, banks, and other financial institutions. In the event counter-parties do not fulfill their obligations, the Company may be exposed to risk. The risk of default depends on the creditworthiness of the counter-party or issuer of the instrument. It is the Company's policy to review, as necessary, the credit standing of each counter-party.

**Note 6: COMMITMENT AND CONTINGENCIES**

The Company had no commitments, no contingent liabilities and had not been named as a defendant in any lawsuit at December 31, 2015 or during the year then ended.

**Note 7: GUARANTEES**

FASB ASC 460, Guarantees, requires the Company to disclose information about its obligations under certain guarantee arrangements. FASB ASC 460 defines guarantees as contracts and indemnification agreements that contingently require a guarantor to make payments to the guaranteed party based on changes in an underlying factor (such as an interest or foreign exchange rate, security or commodity price, an index or the occurrence or nonoccurrence of a specified event) related to an asset, liability or equity security of a guaranteed party. This guidance also defines guarantees as contracts that contingently require the guarantor to make payments to the guaranteed party based on another entity's failure to perform under an agreement as well as indirect guarantees of indebtedness of others.

The Company has issued no guarantees at December 31, 2015 or during the year then ended.

**American Medtech Equity Advisors, LLC**  
**Notes to Financial Statements**  
**December 31, 2015**

**Note 8: SUBSEQUENT EVENTS**

The Company has evaluated events subsequent to the balance sheet date for items requiring recording or disclosure in the financial statements. The evaluation was performed through the date the financial statements were available to be issued. Based upon this review, the Company has determined that there were no events which took place that would have a material impact on its financial statements.

**Note 9: RECENTLY ISSUED ACCOUNTING STANDARDS**

The Financial Accounting Standards Board (the "FASB") has established the Accounting Standards Codification ("Codification" or "ASC") as the authoritative source of generally accepted accounting principles ("GAAP") recognized by the FASB. The principles embodied in the Codification are to be applied by nongovernmental entities in the preparation of financial statements in accordance with GAAP in the United States. New accounting pronouncements are incorporated into the ASC through the issuance of Accounting Standards Updates ("ASUs").

For the year ending December 31, 2015, various ASUs issued by the FASB were either newly issued or had effective implementation dates that would require their provisions to be reflected in the financial statements for the year then ended.

The Company has either evaluated or is currently evaluating the implications, if any, of each of these pronouncements and the possible impact they may have on the Company's financial statements. In most cases, management has determined that the pronouncement has either limited or no application to the Company and, in all cases, implementation would not have a material impact on the financial statements taken as a whole.

**Note 10: NET CAPITAL REQUIREMENTS**

The Company is subject to the Securities and Exchange Commission Uniform Net Capital Rule (SEC rule 15c3-1), which requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 to 1. Rule 15c3-1 also provides that equity capital may not be withdrawn or cash dividends paid if the resulting net capital ratio would exceed 10 to 1. Net capital and aggregate indebtedness change day to day, but on December 31, 2015, the Company had net capital of \$6,015 which was \$1,015 in excess of its required net capital of \$5,000; and the Company's ratio of aggregate indebtedness of \$80 to net capital was 0.0133 to 1, which is less than the 15 to 1 maximum allowed.

**Note**

---

parking @ Newark Airport  
dinner meeting with Fiagon mgmt team

round trip from airport

---

---



 **AmeriTech Advisors**  
708 Third Avenue, 5<sup>th</sup> floor  
New York, NY 10017

February 11, 2016

Tactical Therapeutics, Inc.  
44 Wall Street, Suite 2003  
New York, New York 10005

**SEC**  
**Mail Processing**  
**Section**  
MAR 07 2016  
**Washington DC**  
**404**

Attention: Rashida A. Karmali, JD, Ph.D, MBA, CLP, CEO

Dear Rashida,

This letter agreement (“Agreement”) confirms our mutual understanding that AmeriTech Advisors LLC (“AmeriTech” or “ATA”) has been engaged on an exclusive basis as financial and strategic advisor to Tactical Therapeutics, Inc. (“the Company”) to provide financial advisory and investment banking services to the Company with respect to potential Financial Transactions (defined below) and Strategic Transactions (defined below) pursuant to the terms hereof. ATA may utilize the services of one or more of its affiliates in the performance of its obligations under this Agreement, in which case references herein to ATA shall include such affiliates.

1. ATA, in its capacity as exclusive advisor to the Company, will perform such of the following financial and strategic advisory consulting and investment banking services as the Company may reasonably request:

- (a) ATA will meet with the Company’s management and familiarize itself to the extent it reasonably deems necessary, appropriate and feasible with the business, operations, properties, financial condition and prospects of the Company in order to better determine ways in which ATA can facilitate the Company’s financial and strategic objectives;
- (b) ATA will advise and assist the Company in identifying and evaluating various financial alternatives that may be available for the primary purpose of raising capital for the Company through a private or public sale of equity, debt or convertible securities of the Company (each a “Financial Transaction”), provided that in no event shall a Financial Transaction include issuances of Common Stock, stock options and/or other equity incentives to employees of or consultants to the Company, issuances of equity, debt or convertible securities in any transactions the primary purposes of which are not to raise capital for the Company or any Strategic Transaction, and, provided further, that it is understood and agreed that nothing contained herein shall constitute a commitment by ATA to underwrite, purchase or place any securities;
- (c) ATA will advise and assist the Company in identifying and evaluating strategic alternatives, other than Financial Transactions, that may be available to the Company to enhance shareholder value, including, without limitation, a license or sale of the commercialization rights for one or more of the Company’s products, acquisition

**American Medtech Equity Advisors, LLC**  
**Report Pursuant to Rule 17a-5 (d)**  
**Financial Statements**  
**For the Year Ended December 31, 2015**

**PUBLIC**